Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 14/20 | 0.68 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17686184 | 1.00 | PTGFR (0.68) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL17686189 | 1.00 | PTGFR (0.68) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL17696713 | 0.93 | PTGFR (0.69) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL12119717 | 0.84 | PTGFR (0.74) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL21546227 | 0.84 | PTGFR (0.74) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL30242083 | 0.83 | PTGFR (0.80) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL12119609 | 0.83 | PTGFR (0.73) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL12119720 | 0.83 | PTGFR (0.73) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL3364746 | 0.83 | PTGFR (0.85) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL13008203 | 0.83 | PTGFR (0.81) | PTGFRPTGER3ABCC4ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016441-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | claimed |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | ALCON INC. (CH) | 2017-08-24 | — | — | US | claimed |
| EP-3206693-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | Novartis AG (CH) | 2017-08-23 | — | — | EP | claimed |
| US-9604949-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | claimed |
| WO-2016061370-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2016-04-21 | — | — | WO | claimed |
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | claimed |
| EP-3206693-B1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | ALCON INC (CH) | 2022-08-03 | — | — | EP | disclosed |
| US-10016441-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-10016441-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | ALCON INC. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | ALCON INC. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9604949-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-9604949-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | PTGFR 5/4885PTGER3 14/4885ABCC4 1489/4885 |
| US-10016441-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | PTGIR, PTGIS, PTGS1 | PTGFR 5/4885PTGER3 14/4885ABCC4 1489/4885 |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | PTGFR 5/4885PTGER3 14/4885ABCC4 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.